Key facts
- Accro Bioscience’s last known valuation is $161.0M (Jan 2022).
- It has raised $62.0M; the latest was Later Stage VC ($12.0M) in Mar 2025.
- Notable investors include Suzhou Oriza Holdings Corporation, Shenzhen Capital Group, Hefei Innovation Technology Venture Capital, 5Y Capital, Hongtai Capital Holdings — 10 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for Accro Bioscience
- ·The full record, as it builds
Funding rounds
No funding rounds for Accro Bioscience are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Accro Bioscience
Developer of small molecule innovative drugs designed for inflammatory, autoimmune diseases and cancer. The company focuses on the molecular mechanism of regulated cell death and the related pathogenesis in human diseases, improving the current therapeutic standard of targeted disease areas.
- Sector
- Healthcare
- HQ
- Suzhou, China
- Founded
- 2017
- Website
- accropeutics.com/
- Ownership
- Privately Held (backing)
Accro Bioscience doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Accro Bioscience shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Accro Bioscience in its N-PORT filings yet. We sweep new filings monthly.